Cryotec products were created with the mission to redefine the standards in cryopreservation, ensuring the highest survival rates for oocytes and embryos. Since its inception, Cryotec has been driven by the commitment to provide reliable, effective solutions for fertility clinics worldwide.
With over 5 million cases successfully preserved, our technology is trusted in 67+ countries, empowering embryologists to deliver optimal outcomes for their patients.
Dr. Masashige Kuwayama, Chairman of Reprolife and creator of the Cryotec Method, has revolutionized cryopreservation in Assisted Reproductive Technology (ART). His advancements in solution composition, device design, and vitrification protocols have significantly improved success rates, particularly for oocytes.
In 1991, he made history by successfully vitrifying mammalian blastocysts, marking a new era in reproductive technology. Driven by excellence, he achieved human oocyte vitrification in 1999, expanding reproductive options.
Dr. Kuwayama’s early recognition of the need for a safer oocyte cryopreservation method stems from his desire to provide more opportunities for women in their late 30s facing age-related infertility. By offering flexibility in lifestyle and family planning, his method addresses their specific needs.
Additionally, his approach has proven invaluable for women undergoing cancer treatment, particularly those with blood cancer, who often experience loss of ovarian function and subsequent infertility as a side effect. Through pre-emptive oocyte freezing, these women now have the possibility of future conception. His vitrification methods, initially pioneered in Japan, have become global standards, improving success rates worldwide.
With unwavering dedication, Dr. Kuwayama continues to drive technological advancements, striving for the highest rates of oocyte and embryo survival while ensuring a stress-free vitrification process for embryologists.
Our Cryotec Method, developed by Dr. Kuwayama, overcomes the limitations of previous cryopreservation techniques. This method has been refined to ensure that every oocyte or embryo, whether strong or weak, survives the freezing and warming process without exception.
Our products, which include vitrification solutions, warming plates, and cryogenic containers, are carefully designed to minimize the risks of mechanical injury, osmotic shock, and ice crystal formation—common causes of cell loss.
We are continuously refining our formulations and protocols, making them simpler and more cost-effective for clinics while maintaining the highest standards of success. Our products are FDA-approved, MEA-tested, and trusted by fertility professionals in over 67 countries. We are committed to providing educational resources and in-house training to help embryologists integrate our solutions seamlessly into their labs.
© Reprolife: Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Reprolife with appropriate and specific direction to the original content.